A 4-year trial of tiotropium in chronic obstructive pulmonary disease.
暂无分享,去创建一个
M. Decramer | S. Senn | B. Celli | D. Tashkin | S. Menjoge | S. Kesten | D. Burkhart
[1] Geert Molenberghs,et al. Random Effects Models for Longitudinal Data , 2010 .
[2] P. Calverley,et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. , 2008, American journal of respiratory and critical care medicine.
[3] M. Decramer,et al. Bronchodilator responsiveness in patients with COPD , 2008, European Respiratory Journal.
[4] D. Niewoehner,et al. Premature discontinuation of patients: a potential bias in COPD clinical trials , 2007, European Respiratory Journal.
[5] D. Postma,et al. A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo. , 2007, Chest.
[6] Bartolome Celli,et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.
[7] C. Wentworth,et al. Pooled clinical trial analysis of tiotropium safety. , 2006, Chest.
[8] F. Maltais,et al. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD: Chest 2005;128:1168–78 , 2006 .
[9] S. Suissa. Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease. , 2006, American journal of respiratory and critical care medicine.
[10] V. Brusasco,et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. , 2003, Thorax.
[11] M. Decramer,et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): A randomised placebo-controlled trial: The Lancet 2005;365(9470):1552–60 , 2005 .
[12] C. Wentworth,et al. POOLED CLINICAL TRIAL ANALYSIS OF THE SAFETY OF TIOTROPIUM , 2005 .
[13] D. Niewoehner,et al. Prevention of Exacerbations of Chronic Obstructive Pulmonary Disease with Tiotropium, a Once-Daily Inhaled Anticholinergic Bronchodilator , 2005, Annals of Internal Medicine.
[14] F. Maltais,et al. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. , 2005, Chest.
[15] M. Decramer,et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial , 2005, The Lancet.
[16] A. Anzueto,et al. One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. , 2005, Pulmonary pharmacology & therapeutics.
[17] B. Make,et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD , 2004, European Respiratory Journal.
[18] M. Decramer,et al. Clinical Trial Design Considerations in Assessing Long‐Term Functional Impacts of Tiotropium in COPD: The Uplift Trial , 2004, COPD.
[19] S. Spencer,et al. Withdrawal from treatment as an outcome in the ISOLDE study of COPD. , 2003, Chest.
[20] V. Brusasco,et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. , 2003, Thorax.
[21] R. Zuwallack,et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease , 2002, European Respiratory Journal.
[22] J. V. van Noord,et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium , 2002, European Respiratory Journal.
[23] J. Connett,et al. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. , 2000, The New England journal of medicine.
[24] S. Spencer,et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial , 2000, BMJ : British Medical Journal.
[25] tefan,et al. LONG-TERM TREATMENT WITH INHALED BUDESONIDE IN PERSONS WITH MILD CHRONIC OBSTRUCTIVE PULMONARY DISEASE WHO CONTINUE SMOKING , 2000 .
[26] Alan D. Lopez,et al. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study , 1997, The Lancet.
[27] John L. Hankinson,et al. Standardization of Spirometry, 1994 Update. American Thoracic Society. , 1995, American journal of respiratory and critical care medicine.
[28] W. Bailey,et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. , 1995, JAMA.
[29] P. Jones,et al. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. , 1992, The American review of respiratory disease.
[30] J. Ware,et al. Random-effects models for longitudinal data. , 1982, Biometrics.
[31] R. Peto,et al. The natural history of chronic airflow obstruction. , 1977, British medical journal.